© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bluejay Diagnostics, Inc. (BJDX) stock declined over -2.49%, trading at $1.96 on NASDAQ, down from the previous close of $2.01. The stock opened at $1.91, fluctuating between $1.91 and $1.96 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 23, 2026 | 1.83 | 2.01 | 1.83 | 2.01 | 21.1K |
| Mar 20, 2026 | 1.79 | 2.05 | 1.78 | 2.02 | 44.18K |
| Mar 19, 2026 | 1.80 | 1.95 | 1.80 | 1.95 | 7.07K |
| Mar 18, 2026 | 1.81 | 1.86 | 1.77 | 1.85 | 27.09K |
| Mar 17, 2026 | 1.94 | 1.94 | 1.86 | 1.89 | 13.5K |
| Mar 16, 2026 | 1.91 | 1.95 | 1.83 | 1.95 | 11.44K |
| Mar 13, 2026 | 1.98 | 1.98 | 1.84 | 1.90 | 14.66K |
| Mar 12, 2026 | 2.01 | 2.04 | 1.94 | 1.98 | 14.59K |
| Mar 11, 2026 | 1.99 | 2.04 | 1.90 | 2.03 | 13.75K |
| Mar 10, 2026 | 1.87 | 2.05 | 1.76 | 1.92 | 77.5K |
| Mar 09, 2026 | 1.85 | 1.91 | 1.70 | 1.87 | 40.53K |
| Mar 06, 2026 | 1.90 | 1.90 | 1.78 | 1.86 | 54.54K |
| Mar 03, 2026 | 1.93 | 1.95 | 1.80 | 1.95 | 34.65K |
| Mar 02, 2026 | 1.99 | 2.05 | 1.99 | 2.05 | 22.42K |
| Feb 27, 2026 | 2.03 | 2.09 | 1.99 | 2.05 | 24.11K |
| Feb 26, 2026 | 1.99 | 2.07 | 1.98 | 2.06 | 38.88K |
| Feb 25, 2026 | 1.94 | 2.10 | 1.94 | 2.03 | 85.86K |
| Feb 24, 2026 | 1.92 | 2.10 | 1.88 | 2.05 | 115.69K |
| Feb 23, 2026 | 1.81 | 2.19 | 1.79 | 1.94 | 223.06K |
| Feb 20, 2026 | 2.01 | 2.26 | 1.78 | 2.02 | 5.12M |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Employees | 7 |
| Beta | 0.72 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |